Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Trial Profile

An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors SK Life Science
  • Most Recent Events

    • 27 Jul 2023 Results (n=240) of post-hoc analysis describing sustainability of seizure reduction and seizure control with adjunctive cenobamate ,published in Epilepsia.
    • 29 Jun 2023 According to an Endo International media release, XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy received approval from Health Canada.
    • 27 Apr 2023 Results (n=214) of post-hoc analysis predictors of achievement of response with cenobamate presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top